and kidney or liver dysfunction. These complica tions influence the patient's life expectancy and quality of life. 6, 7 The characteristic hemodynamic derangement in Fontan circulation causing liver abnormalities and pathology is commonly identified as Fontan associated liver disease (FALD). 2, 8 This can lead to nodular hyperplasia, cirrhosis, and hepatocel lular carcinoma associated with ascites, variceal bleeding, and encephalopathy. Moreover, it is re lated with higher late morbidity and mortality in this particular population. 8 -10 Recent studies have shown that elevated ve nous pressure (3 to 4 fold in comparison with functional class, vital signs, weight, height, echo cardiography, and SWE.
The severity of liver disease was assessed us ing the Child-Pugh scale (including total bili rubin, albumin, international normalized ratio [INR] level, presence of ascites, and encephalop athy), VAST score (including the presence of var ices, ascites, splenomegaly, or thrombocytope nia), and Model For End stage Liver Disease Ex cluding INR (MELD XI). According to the stage of LS assessed by SWE, patients were divided into 2 subgroups depending on the stage of fi brosis: group 1 (METAVIR stage 1 or 2 [F1, F2]) and group 2 (METAVIR stage 3 or 4 [F3 and F4]).
The study protocol was approved by the local ethics committee (No. 1072.6120.110.2017). Each participant provided informed consent prior to participation in this study.
Laboratory tests
The following laboratory pa rameters were measured: red blood cell count, hematocrit, hemoglobin, red blood cell dis tribution width, N terminal fragment of the prohormone brain natriuretic peptide (NT proBNP), as well as liver function markers in cluding serum protein electrophoresis, ALT, AST, γ glutamyltranspeptidase (GGTP), alkaline phos phatase (ALP), total bilirubin level, α fetoprotein, and serologic tests for hepatitis B and C.
Furthermore, the following tests for liver fi brosis assessment were performed, allowing an estimation of several parameters calculated according to specific formulas: platelet count, AST/ALT ratio, 11,19,21 APRI, 19-21 FIB 4 score, 19, 20 Forns index, 19,20,22, 23 and MELD XI score. 20, 24, 25 Echocardiography Single ventricular ejection fraction (SVEF) and valvular competence were evaluated and semiquantified by 2 experienced cardiologists using echocardiography (Vivid 7 GE Medical System, Chicago, Illinois, United States). normal) affects portal pressure and is common among patients with Fontan circulation. As a con sequence, it can drive the activation and transfor mation of stellate cells into collagen depositing myofibroblasts and increase proinflammatory activity, leading to liver fibrosis. 2,11,12 Howev er, the pathogenesis of FALD is different and more complex than in other liver diseases, such as chronic hepatitis. 12 Although percutaneous liver biopsy is the stan dard method for the diagnosis and evaluation of liver fibrosis, noninvasive tests (including bio chemical tests, shear wave elastography [SWE], and magnetic resonance elastography) have be come more clinically relevant and useful, with good sensitivity and specificity in the detec tion and evaluation of the degree of liver dis ease among patients with various hepatic dis orders, including FALD. Fibrosis scores such as the ratio of aspartate transaminase (AST) to al anine transaminase (ALT) (AST/ALT ratio), AST to platelet ratio index (APRI), Forns index, and fibrosis 4 (FIB 4) score are based on widely used biochemical and clinical parameters. 7-9,13, 14 Shear wave elastography is the most accurate noninvasive method for the evaluation of liver stiffness (LS) 15, 16 and shows a positive correla tion between histologic liver damage and stiff ness. 17, 18 This technique has been validated for most hepatic diseases and has reduced the num ber of liver biopsies performed, along with the oc currence of possible complications such as bleed ing, abdominal pain, or peritonitis.
Currently, effective methods for the diagno sis of FALD and the main factors influencing the degree of liver fibrosis are popular research areas. The aim of our study was to evaluate, in a long term follow up, the degree of LS using SWE among adult patients who had undergone the Fontan procedure and to investigate the re lationship between patient characteristics (such as medical history, laboratory parameters, and echocardiographic data) and the degree of LS in these patients. Patients were followed for a min imum of 6 months (up to 24 months).
PATIENTS AND METHODS Patients
This retro spective study included 59 adult patients with Fontan circulation, followed at the Depart ment of Cardiac and Vascular Diseases, Insti tute of Cardiology in Kraków, Poland, between 2015 and 2017. The exclusion criteria were as follows: current infection, inflammation, major trauma, pregnancy, diabetes, and history of al cohol abuse.
Study protocol The following information was recorded for each patient in the study: type of cardiac malformation, history of cardiac opera tions, age at the time of surgical repair, type of systemic ventricle, comorbidities (protein losing enteropathy, arrhythmia), laboratory tests, ox ygen saturation, New York Heart Association Echocardiography The mean SVEF was 51.4% (9.5%). Atrioventricular valve regurgitation was mild in 28 patients (47%); moderate, in 16 (27%); and severe, in 3 (7%). In 11 patients (19%), atrio ventricular valve regurgitation was minimal. Fen estration was seen in 30 patients (51%). Other echocardiographic findings included: left ven tricular noncompaction (1 patient), coarctation of the aorta (1 patient), coronary right ventricu lar fistula (1 patient), pericardial effusion (2 pa tients), aortic aneurysm (1 patient), and aortic valve regurgitation (21 patients: moderate in 9 patients and mild in 12 patients).
Biochemical test results Laboratory test results are presented in TABLE 2. Hepatitis serology was positive in 6 patients (4 had chronic hepatitis B and 2 had chronic hepatitis C). Among liver pa rameters, elevated indirect bilirubin levels were the most frequent abnormality (80% of patients). High GGPT levels and low total platelet count were observed in 68% of patients. The INR was increased in 18 patients (42% of patients who were not receiving therapy with vitamin K an tagonists). Reduced total protein levels were ob served in 12% of patients, and abnormal albu min levels, in 8%. Protein losing enteropathy was observed in 9 patients (15%). Hepatic fibro sis scores, based on laboratory test results such as the AST/ALT ratio, platelet count, APRI score, Forns index, and FIB 4 score, are also shown in (TABLE 3) . Accord ing to the Child-Pugh scale of liver cirrhosis se verity, 40 patients (78%) were in class A; 10 pa tients (20%), in class B; and 1 patient (2%) in class C. The median MELD XI score was 9.7 (IQR, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Moreover, 2 patients were diagnosed with hepatocellular carcinoma.
Abdominal ultrasonography Abdominal ultraso nography was performed in 44 patients. Hepa tomegaly was present in 17 patients (43%), and splenomegaly, in 21 (48%). Increased echogenici ty was observed in 14 patients (32%), and liver surface nodularity, in 19 (44%). In 11 patients (25%), liver heterogeneity was shown.
Shear wave elastography of the liver Shear wave elastography was performed in 54 patients. The median LS was 9.1 kPa (IQR, 3.9-18.5 kPa). Five of these patients (9%) had LS stage 1 (F1); 14 (26%), stage 2 (F2); 28 (52%), stage 3 (F3); and 7 (13%), stage 4 (F4).
The analysis of laboratory parameters in terms of LS (group 1 vs group 2) showed that patients with stages F3 and F4 had higher AST Statistical significance was set at a P value of less than 0.05. Statistica version 13 (StatSoft Inc., Tulsa, Oklahoma, United States) was used to analyze the data. Two patients died during the follow up (the first patient due to heart failure, and the second, due to heart failure with concomitant hepatocel lular carcinoma). diameter was 8 mm (IQR, 5-13 mm). The medi an systolic to diastolic velocity ratio was 2.0 (1.2-4). The MPV and splenic vein diameters did not differ between groups. Three patients (7%) had a planar spectrum of the MPV flow. We did not reveal any correlations between LS and splenic and MPV diameters. In addition, no correlation was observed between the MPV di ameter and systolic to diastolic velocity ratio. The splenic vein diameter negatively correlated with the platelet count (r s = -0.5). No significant correlation was seen between vascular Doppler pa rameters and other clinical features (type of sur gery, ventricular morphology, time after the Fon tan procedure, age at surgery, SVEF, or atrioven tricular valve regurgitation). levels compared with patients with stages F1 and F2 (P = 0.01). Also, GGTP levels and platelet count were different between groups (P = 0.01 and P = 0.02, respectively). The comparison of other com mon liver parameters (ALT, ALP, total bilirubin, α fetoprotein, and total protein and albumin), he matologic parameters (red blood cell count, hemo globin, hematocrit), creatinine, and NT proBNP, did not show significant differences between groups. We also assessed the differences in liver fibrosis scores (AST/ALT ratio, APRI, FIB 4, score, and Forns index) between groups 1 and 2 (TABLE 2). The APRI, FIB 4 score, and Forns index were signif icantly higher in group 2 than in group 1 (TABLE 2). Vascular Doppler Vascular Doppler was per formed in 41 patients. The mean (SD) MPV diam eter was 10 (1.9) mm, and the median splenic vein the 5 year survival rate, 35%. Considering that hepatocellular carcinoma is associated with high mortality, FALD may be one of the major determi nants of mortality in adult patients after the Fon tan procedure.
RESULTS
Time after the Fontan procedure was report ed as a possible factor influencing the degree of liver fibrosis. 8,12,26 This is supported by our cur rent study, which showed that LS and liver fibro sis are strongly related to time after the Fontan procedure. These findings are in line with previ ous observations by Goldberg et al. 12 Our study also showed that the patient age at the time of the Fontan procedure is another possible factor influencing liver fibrosis. Duorsola et al 27 demon strated that LS increased rapidly after total cavo pulmonary connection. This could be a result of the new hemodynamic status immediately after the total cavopulmonary connection, with a dis proportion between liver outflow and portal flow, which is not proportionally reduced.
Of note, our findings disagree with those of Johnson et al, 28 who showed that increased pa tient age at the time of the Fontan procedure correlated with a higher grade of sinusoidal fi brosis. It has to be stated, however, that their study was a retrospective postmortem analysis, with a median interval of 14 days from the Fon tan procedure to death, limited to a small group of patients who underwent the Fontan proce dure at an advanced age and who had predomi nantly atriopulmonary Fontan connections. On the other hand, several studies demonstrated that LS increases even before the Fontan proce dure, after the Glenn procedure, or directly after the Fontan procedure. 29, 30 The chronic low pre load of a univentricular heart results in remodel ing, reduced compliance with increasing diastol ic pressure, low ventricular filling leading to car diac output decrease, and liver hypoperfusion. 31
Correlation between liver stiffness and biochemical findings
The degree of LS correlated with the plate let count (r s = -0.33), GGTP levels (r s = 0.37), and AST levels (r s = 0.33). Furthermore, LS was as sociated with higher APRI (r s = 0.38), FIB 4 score (r s = 0.35), and Forns index (r s = 0.29). The cor relations are presented in FIGURES 1-3. Other clini cal parameters, including age, age at procedure, time after the Fontan procedure, single ventric ular morphology, SVEF, degree of atrioventric ular valve regurgitation, and biochemical liver test results did not correlate with LS as assessed by SWE.
The canonical correlation analysis was used to assess the effect of individual factors on LS and thrombocytopenia. We established a significant model that included age of the patient at the time of the Fontan procedure, time after Fontan pro cedure, and SVEF. The analysis indicated that LS and thrombocytopenia were strongly related to time after the Fontan procedure, with a loading vector of 0.797. Increased LS and thrombocy topenia were associated with age at the Fontan procedure, with a loading vector of -0.434, and SVEF, with a loading vector of -0.49.
DISCUSSION
Our study was designed to evaluate liver status and the degree of LS, using noninva sive methods in 59 adult patients after the Fontan procedure. One of the most important findings is that all patients who had undergone the Fontan procedure had developed various stages of LS in a long term follow up, as assessed by SWE. Fur thermore, 65% of patients with stages F3 or F4 of fibrosis had an advanced stage of LS 20 years af ter the procedure, as compared with 35% of pa tients with stages F1 or F2. Moreover, 13% of patients were diagnosed with hepatic cirrhosis, while 2 patients, with hepatocellular carcinoma. Pundi et al 10 reported that the 1 year survival rate of patients with liver cirrhosis was 57%, and the best predictor of advanced liver damage. Ad ditionally, the MELD XI score can be used to as sess eligibility for liver transplant. 18 In our study, patients with an advanced stage of hepatic fibro sis (F3, F4) had higher MELD XI scores than pa tients with stages F1 and F2; however, the differ ence was not significant. Indications for heart transplantation alone or a combined heart and liver transplant are cur rently widely debated. Recent studies have sug gested that a combined heart and liver transplant can be considered in the treatment of patients with failing Fontan circulation. Furthermore, ad vanced liver fibrosis and cirrhosis should not be a contraindication to heart transplant in these patients. 38 Conversely, Lin et al 21 reported that double transplant in patients with compensated liver disease may be too aggressive. Importantly, other studies documented the possibility of liv er function improvement or even liver fibrosis resolution when heart function is restored (af ter heart transplant) in patients with a cardiac origin of fibrosis. 39 Further studies in a population with function ally univentricular heart are needed to better se lect candidates for heart transplant or combined heart and liver transplant. Moreover, a personal ized approach with innovative surgical and med ical methods is required to provide optimal care to this patient group. 40
Study limitations
Our study has several limita tions. The study group was limited, and the pop ulation was heteroge neous regarding their ini tial diagnoses and the type of Fontan surgery. Furthermore, the study was performed in a sin gle center; however, to the best of our knowl edge, the study includes the largest number of adult patients after the Fontan procedure in Pol ish population. Finally, the liver fibrosis stage was assessed noninvasively only due to the high risk of liver biopsy complications. Only 2 patients in our cohort with a suspicion of hepatocellular carcinoma underwent liver biopsy. In our study, we used SWE to estimate the LS and liver fibro sis degree as well as to validate the utility of LS scores derived from the available clinical param eters. We proved the usefulness of these scores as noninvasive markers of the liver status in routine follow up. It has been widely recognized, howev er, that the noninvasive methods for LS estima tion have their inherent limitations. For exam ple, transient elastography in FALD is problem atic because of other causes of hepatic stiffness, for example, vascular congestion. Nevertheless, a real time 2 dimensional SWE can monitor liver fibrosis by measuring tissue elasticity (ie, elastic modulus). Moreover, SWE is more accurate than transient elastography in detection of significant fibrosis. Finally, Kutty et al 19 reported that SWE showed a positive correlation between histolog ical liver damage and rigidity. This is in line with our findings, as we demon strated that the SVEF is another significant fac tor related to the stage of LS.
The diagnosis and assessment of FALD is dif ficult, because the disease frequently remains as ymptomatic over a long period of time. Moreover, our study showed that most of the biochemical markers commonly used in clinical practice did not correlate with LS, with the exception of AST, GGTP, and platelet count. Recent studies have reported that patients with Fontan circulation have abnormal liver parameters and coagulation factors. 26,32 According to some authors, FALD is mostly associated with normal or only mildly increased levels of liver parameters. 11, 33 A multi center study by Carter Kent et al 34 revealed that elevated AST levels were the only biochemical pa rameter associated with the degree of liver fibro sis. A study by Lindsay et al 9 showed that AST lev els were significantly higher in patients with ad verse liver outcomes (including symptomatic syn thetic hepatic dysfunction, hepatocellular carcino ma or adenomatosis, and hepatorenal syndrome requiring liver transplant), when compared with the subgroup without adverse liver outcome.
A platelet count of less than 150 × 10 3 /µl is a hallmark of hypersplenism, usually the first and sometimes the only feature of portal hyper tension. Furthermore, a serial decrease in plate let count may correlate with hepatic fibrosis, and even a slight decrease in platelet count may be significant enough to diagnose liver fibrosis and hypersplenism. 4, 35 In our study, thrombocytope nia strongly correlated with time after the Fon tan procedure and SVEF.
In our study, 16 patients (30%) had features of portal hypertension according to the VAST scale. As described by Elder et al, 13 patients with features of portal hypertension, such as varices and ascites, have a 9 fold higher risk of adverse events such as death, requirement for transplan tation, or hepatocellular carcinoma.
Due to the invasiveness of liver biopsies, a number of fibrosis scores were created as a non invasive method for liver fibrosis assessment. They are currently used in clinical practice to di agnose and assess liver fibrosis in adult patients with hepatitis B and C, alcoholic fatty disease, and nonalcoholic fatty liver disease. 19, 36 Fibrosis scores are based on biochemical and clinical pa rameters widely used in clinical practice, such as the AST/ALT ratio, APRI, Forns index, and FIB 4 score. Although these parameters have not yet been validated in patients with FALD, there are several studies documenting the use of nov el hepatic fibrosis scores. 13,18,37 However, most of those studies were conducted on a pediatric population. Our study showed that the stage of LS, as measured by SWE, is associated with high er liver fibrosis scores. Patients with higher LS (stage F3 or F4) had significantly higher APRI, FIB 4 score, and Forns index, when compared with patients in stages F1 and F2. Interestingly, Téllez et al 18 demonstrated that the Forns index is Conclusions Our study revealed that adult patients after the Fontan procedure tend to develop liver dys function in a long term follow up. The pathomech anism of liver impairment is complex and multifac torial. Time after surgery, age at the time of the pro cedure, and SVEF are strongly related to the degree of LS as assessed by SWE. Moreover, SWE and liv er fibrosis scales based on biochemical and clinical parameters such as the APRI, Forns index, and FIB 4 score may be helpful in assessing the severity of liver fibrosis. Therefore, they should be considered in regular noninvasive hepatic monitoring to diag nose FALD and initiate early treatment in patients with functionally univentricular heart.
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